This site is intended for healthcare professionals
Cancer-Associated Thrombosis
Declaration of sponsorship Pfizer and Bristol Myers Squibb

VTE risk

Declaration of sponsorship Pfizer and Bristol Myers Squibb
Ongoing cutting-edge research provides insights into the risk of cancer-associated thrombosis (CAT), the pathophysiology of the disease and how risk stratification is essential to guide treatment choices.

Cancer-associated thrombosis (CAT) is a common cause of death amongst the cancer population. 

The increased risk of recurrent venous thromboembolism (VTE) and bleeding complications in patients with cancer makes anticoagulant treatment and management of VTE challenging1

Register for free access to this exclusive healthcare learning resource


Why sign up with Medthority?

Develop your knowledge with our disease and condition focused Learning Zones

Access content from credible sources, including expert-led commentary, videos, podcasts, and webinars as well as clinical trials, treatment information and guidelines 

Personalised dashboard providing updates and recommendations for content within your areas of interest

The pathophysiology of VTE includes general and biological risk factors, common to cancer and non-cancer patients, however in patients with malignancy there are an additional number of disease-specific factors, which render the pathogenesis unique11.

The thrombotic generation process in the cancer patient is distinct from the non-cancer population.

Register for free access to this exclusive healthcare learning resource


Why sign up with Medthority?

Develop your knowledge with our disease and condition focused Learning Zones

Access content from credible sources, including expert-led commentary, videos, podcasts, and webinars as well as clinical trials, treatment information and guidelines 

Personalised dashboard providing updates and recommendations for content within your areas of interest

The incidence of VTE increases exponentially with the increase in presented risk factors. 

A thorough risk score system and risk stratification is essential to help physicians plan particular prophylactic approaches for patients prone to develop the disease12

Register for free access to this exclusive healthcare learning resource


Why sign up with Medthority?

Develop your knowledge with our disease and condition focused Learning Zones

Access content from credible sources, including expert-led commentary, videos, podcasts, and webinars as well as clinical trials, treatment information and guidelines 

Personalised dashboard providing updates and recommendations for content within your areas of interest

References

  1. Agnelli, G. et al. Apixaban for the treatment of venous thromboembolism associated with cancer. N. Engl. J. Med. 2020;382:1599–1607
  2. Kushner, A., West, DO, W. P. & Pillarisetty, L. S. Virchow Triad. StatPearls (StatPearls Publishing, 2019).
Register for free access to this exclusive healthcare learning resource


Why sign up with Medthority?

Develop your knowledge with our disease and condition focused Learning Zones

Access content from credible sources, including expert-led commentary, videos, podcasts, and webinars as well as clinical trials, treatment information and guidelines 

Personalised dashboard providing updates and recommendations for content within your areas of interest

Welcome: